SURROGATE END-POINT BIOMARKER (SEB) GUIDED DRUG DEVELOPMENT - A PRACTICAL STRATEGY FOR CHEMOPREVENTION (CP) OF PREINVASIVE CANCER (PRECA)

Authors
LIEBERMAN R BOONE C CROWELL J HAWK E MALONE W STEELE V LUBET R SIGMAN C KELLOFF G
Citation
R. Lieberman et al., SURROGATE END-POINT BIOMARKER (SEB) GUIDED DRUG DEVELOPMENT - A PRACTICAL STRATEGY FOR CHEMOPREVENTION (CP) OF PREINVASIVE CANCER (PRECA), Clinical pharmacology and therapeutics, 61(2), 1997, pp. 1-1
Citations number
NO
Categorie Soggetti
Pharmacology & Pharmacy
Journal title
Clinical pharmacology and therapeutics → ACNP
ISSN journal
00099236
Volume
61
Issue
2
Year of publication
1997
Pages
1 - 1
Database
ISI
SICI code
0009-9236(1997)61:2<1:SEB(GD>2.0.ZU;2-3